drugset / Trial / NCT00536939
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine efficacy and safety of paclitaxel, bevacizumab and enzastaurin versus paclitaxel, bevacizumab, and placebo in participants who are diagnosed with locally recurrent or metastatic breast cancer.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-03
- Completion
- 2008-03
Outcome
Outcome not reported
Stopped (Enrollment): “Study has been terminated due to slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | enzastaurin | Small molecule | 500 mg | Oral |
| Background | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Paclitaxel | Small molecule | 90 mg/m2 | Intravenous |